Antigen News and Research

RSS

OncoSec signs agreement with Inovio to purchase non-DNA cancer vaccine technology

OncoSec Medical Inc., a developer of innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs, announced today that it has signed an agreement with Inovio Pharmaceuticals, Inc. providing for the purchase by OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

15 Mar 2011

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Oxford BioMedica plc, a leading gene therapy company, today announces that further analyses of the TroVax Renal Immunotherapy Survival Trial, a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology, Immunotherapy, the official journal of the Association for Cancer Immunotherapy.

15 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Biotechnology company MabCure, Inc. is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists.

9 Mar 2011

Debate continues regarding certain medical tests

News outlets report on how discussion continues to swirl around the use of the so-called "PSA velocity" test and mammography guidelines.

8 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011

Summer Street Research announces recent closing of financing for IMUC

Summer Street Research Partners is pleased to announce the recent closing of a financing for ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

5 Mar 2011

IMMY, University of Nevada, Reno collaborate to make new blood test for Cryptococcosis

A new, rapid blood test that could lead to early diagnosis and potentially save the lives of hundreds of thousands of people stricken with fungal meningitis, a leading cause of AIDS-related deaths in developing countries, is getting closer to market with a recent collaboration between the University of Nevada, Reno and Immuno-Mycologics in Oklahoma.

5 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

Affymetrix releases complete genotyping data set on its website

Affymetrix, Inc. today announced the release of a complete data set of 5 million variants on its website.

3 Mar 2011

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine.

3 Mar 2011

New microfluidic device may help clinicians to improve cancer therapy

Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.

3 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.

1 Mar 2011

New research reveals how maternal antibodies block immune response to measles virus

New research that reveals how maternal antibodies block an immune response to the measles virus is a first step toward improving current childhood vaccination practices, scientists say.

1 Mar 2011

New nasal vaccine holds promise against both Alzheimer's disease and stroke

One in eight Americans will fall prey to Alzheimer's disease at some point in their life, current statistics say. Because Alzheimer's is associated with vascular damage in the brain, many of them will succumb through a painful and potentially fatal stroke.

1 Mar 2011

Steroid administration may impact immune system in children with asthma

Children experiencing an asthma attack who are treated with a short burst of oral steroids may have a transient depression of immune response according to a new study led by Universit- de Montr-al.

24 Feb 2011

Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

A $200,000 grant from the Rhode Island Science and Technology Advisory Council is helping a Bryant University biochemist find a treatment for a fungal infection that is often lethal to premature infants.

23 Feb 2011

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

NYBC urges African American, Hispanic descent to donate blood for special patients

A hospitalized single mother from Queens is calling for more African Americans to become blood donors, so that she and many others may be able to live. People may call New York Blood Center at 1-800-933-BLOOD or visit www.nybloodcenter.org for more information about giving blood, and where to donate.

22 Feb 2011

Antigen News and Research

OncoSec signs agreement with Inovio to purchase non-DNA cancer vaccine technology

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Debate continues regarding certain medical tests

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Summer Street Research announces recent closing of financing for IMUC

IMMY, University of Nevada, Reno collaborate to make new blood test for Cryptococcosis

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Affymetrix releases complete genotyping data set on its website

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

New microfluidic device may help clinicians to improve cancer therapy

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

New research reveals how maternal antibodies block immune response to measles virus

New nasal vaccine holds promise against both Alzheimer's disease and stroke

Steroid administration may impact immune system in children with asthma

Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

Why are Chlamydia and HPV major public health problems?

NYBC urges African American, Hispanic descent to donate blood for special patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News